In short. Separating the histology, the approved indication and the general cosmetic use, and grading each of the three on its own.
Key points
- A material can have good evidence for one purpose and thin evidence for another, and the same material is described in the same confident way for both.
- The useful question is not how well studied the material is but how well studied the use being proposed is.
The evidence in this category is not one body of work. It is three, with three different strengths, and grading them separately is the only way to describe it accurately.
The histology
The most consistent finding is that injection produces a tissue response with new collagen deposited around the material, and that the material remains identifiable afterwards. This is reported in tissue studies and it is not seriously disputed. Its limits are the limits of histology as evidence about appearance: it describes fibres in a sample and says nothing directly about what a person sees. As evidence that a biological process occurs, it is good. As evidence of a visible result, it is not evidence at all.
The approved indication
The second body of evidence supports the named indication — facial fat loss associated with an illness — and it is the strongest clinical evidence in the group, because an authorisation for a named condition requires an assessment for that condition. It is also the narrowest, and it applies to a defined population with a defined problem rather than to anybody wanting a change in appearance. The distance between that indication and general cosmetic use is where most claims on this site live.
Strengths attach to uses, not to materials
A material can have good evidence for one purpose and thin evidence for another, and the same material is described in the same confident way for both. The useful question is not how well studied the material is but how well studied the use being proposed is.
The cosmetic use
The third body of evidence concerns general cosmetic use, and it is limited. The trials are small, they are few, they differ in what they measure, and few of them follow people long enough to show how a result behaves over a year. Some report improvement in appearance scores; the measures vary enough between studies that comparing them is difficult. The honest description is that there is evidence, that it is weak, and that it is weaker than the mechanism story suggests and stronger than a blanket dismissal would allow.
Why the studies are hard to read together
Because the materials differ, the volumes used differ, the sites differ and the outcome measures differ. A review that pools them is pooling different substances injected in different ways and judged by different standards, and a finding about the pooled group may describe none of its members. That is the strongest argument for grading by material and by use rather than by category.
How to weigh a study you are shown
- Which material, at which site, and at which volume — and is that the combination proposed for you?
- What outcome was measured, and was it a tissue finding or something a person could see?
- How long did it run, and is that long enough to show how a result behaves over a year or more?
Grading by material and by use keeps a real histology finding from being spent on a cosmetic claim that a different body of evidence would have to support.
Frequently asked questions
What is the strongest evidence in this category?
The histology and the approved indication. The tissue response is reproducible and reported consistently, and the named indication rests on an assessment carried out for that purpose. Both findings are narrow, and both are more solid than anything supporting general cosmetic use.
How strong is the evidence for cosmetic use?
Limited. The trials are small, they are few, they use different measures of what counts as an improvement, and they rarely run long enough to show how a result behaves over a year or more. That is why the grade is limited rather than established, and why it is not zero either.
Does a tissue response count as evidence of a result?
It is evidence that a process occurred. Whether it is evidence of a result depends on what a person would see, which is a separate measurement. Treating the first as the second is the most common error made about this category, and it is made in both directions.
Risks & Limitations
- Nothing reverses these materials: no approved agent dissolves them, so a result that is unwanted cannot be injected away.
- Lumps can form around the injected material, more readily in some sites and materials than others, and they cannot be dissolved.
- A named approval covers facial fat loss after an illness, and general cosmetic use sits outside it.
- Histology shows a tissue response; how much visible change it produces is a separate question the studies were not designed to answer.
- The change develops over months, so a person commits to further treatment before knowing how their own tissue responds to the first injection.
When to Seek Care
- A lump, firmness or discolouration in a treated area — have it assessed by a clinician.
- Persistent pain, or skin that is changing colour or blistering after an injection.
- Any change in vision, or severe pain around the eye — seek emergency care immediately.
- Contact the service that performed the treatment, or the hospital’s outpatient channels, rather than relying on a website.
References & Further Reading
- U.S. Food and Drug Administration (FDA) — approved injectable devices and their named indications
- European Medicines Agency (EMA) and national regulators — dermal filler and injectable safety communications
- National Medical Products Administration (NMPA, China) — approved injectable products and their indications
- Cochrane Library — systematic reviews of injectable treatments for facial volume loss
- Chinese Medical Association Plastic Surgery Branch — clinical guidance
This page is patient education, not medical advice, and it does not cite individual studies. It reviews evidence and regulation; it is not a booking page and does not recommend a treatment. Discuss your own case with a qualified clinician. To ask a question about this review, see Contact & Consultation.